The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by 3 months to March 3, 2027, for the new drug ...

The FDA has granted final approval to a laurylsulfate salt formulation of cabozantinib (Omcazio), converting the product’s ...

Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice ...

Burnout remains a significant concern among oncologists, with approximately 60% of oncologists reporting burnout, according ...

The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed ...

Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Early results from the phase 2 RESTORE-PV trial suggest that the investigational monoclonal antibody DISC-3405 has the ...

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...

Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials ...

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

In the patient-only intervention group, the rate of skin self-examination and physician skin examination increased from 15.8% at baseline to 47.5% at 12 months; in the group that also had outreach to ...

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Dr Saro Armenian explains.